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Introduction
Breast cancer is one of the most common cancers and is a leading cause of mortality in women. Prevention and cure of breast cancer represents a challenge for current oncology. Population studies have shown that treatment with the antidiabetic biguanide metformin significantly reduced cancer risk. [1] [2] [3] [4] In animal studies it was revealed that metformin suppresses the mammary carcinoma development in transgenic HER-2/neu mice, 5 mammary carcinogenesis induced by N-nitrosomethylurea in rats, 6 but not that of spontaneous mammary tumors in female SHR mice. 7 It was shown that HER-2 oncoprotein represent a key cellular target in inhibitory effect of metformin on HER-2/neu-poisitve breast cancer cells. 8 Co-incubation with inhibitors of reactive oxygen species (ROS) production significantly enhanced the ability of metformin to suppress HER-2 expression. 8 In our experiments, nocturnal administration of melatonin with drinking water suppressed expression of HER-2 oncogene and inhibited tumorigenesis in the HER-2/neu transgenic mice. 9 Treatment with melatonin inhibits development of mammary tumors in a number of another models both in vitro and in vivo. [10] [11] [12] In this paper, we for the first time present the results of study of effect of combined treatment with metformin and melatonin on some aging related biological parameters, on the survival and Population studies have shown that treatment with the antidiabetic biguanide metformin significantly reduced cancer risk. In our animal studies, metformin delayed the onset of mammary adenocarcinoma (MAC) in transgenic HeR-2/neu mice but not the onset of spontaneous mammary tumors in female SHR mice. pineal hormone also inhibits mammary carcinoma development in HeR2/neu transgenic mice as well as in female SHR mice. Here we demonstrated that a combination of metformin and melatonin significantly inhibits growth of transplanted tumors in mice. Metformin (0.5 mg/ml in drinking water) increased mean life span by 8% and MAC latency by 13.2% (p < 0.05) in HER2/neu mice. The treatment with melatonin alone (2 mg/L in drinking water during the night time) or combined treatment with metformin (0.5 mg/ ml in drinking water during the day time) + melatonin (2 mg/L in drinking water during the night time) did not influence mammary carcinogenesis in the mice. the treatment metformin alone inhibited the growth of transplantable HeR2 mammary carcinoma in FVB/N male mice by 46% at the 45 th day after transplantation (p < 0.001). the combined treatment with metformin + melatonin significantly suppressed Ehrlich tumor growth (by 40%, p < 0.001). These results suggest that metformin may be useful in prevention and treatment of breast cancer.
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times as compared with the mice consumed metformin only during day time over all the period of observation. It means that in the group treated with metformin + melatonin the daily dose of metformin in this group was significantly less than that in the group treated with metformin alone. Age-related dynamics of body temperature in mice. There was 14% decrease in average body temperature at the age of 3 months in the group treated with melatonin alone as compared with age-mated controls. However there was no difference in average body temperature between control and any other groups at any other periods of observation ( Table 2) .
Age-related dynamics of estrous function in mice. The length of estrous cycles in the control female HER-2/neu mice was not significantly changed with age, and slightly increased in all other groups, the change being significant only in the mice treated with metformin + melatonin ( Table 3) . The relative number of long estrous cycles was increased with age in all groups however it was much higher in melatonin and metformin + melatonin groups in comparison with that in the control or metformin alone treated groups. There were no any significant differences in the pattern of age-related changes in the rate of mice with regular and irregular estrous cycles in all groups.
Survival and longevity of female HER-2/neu transgenic mice. According to the log-rank test 13 the difference in survival of female transgenic HER2/neu mice subjected to metformin treatment, compared to the control group, is not significant (p-value is 0.2136) as well as the difference between the controls and mice exposed to metformin + melatonin or to melatonin alone ( Fig. 2A) . Metformin treatment increased mean (+7%) but not maximal life span of female transgenic HER2/neu mice (Table 4) . However, at the time of 50% and 25% mortality in the control group were surviving 90% and 50% of mice in the metformin-treated group, decrease in food consumption between the age of 5 and 8 months and was similar to the controls at other periods. In mice treated with both metformin and melatonin the food consumption was decreased by 15% at the age of 5 months and by 43% at the age 6 months, however at the age of 10 months was increased by 45% as compare to the controls ( Table 1) .
Age-related dynamics of water consumption. The total amount of water consumed by mice varied during the period observation and was practically same in all groups (Fig. 1A) . The calculation of separately of amount of water consumed during the night time has shown that the mice of melatonin and metformin + melatonin-treated groups consumed equal amount of melatonin during the night period. However the amount of water consumed by the mice treated with metformin only (during a night plus over night) was more in average by 2.4 metformin + melatonin inhibited the growth of transplantable HER2/neu mammary carcinoma in male FVB/N mice ( Fig.  3A) and shifted to right a survival curve of tumor-bearing animals ( Fig. 3B) , whereas the treatment with metformin alone inhibits the tumor growth only at the 45 th day after tumor transplantation (by 49%, p < 0.001). Treatment with melatonin alone failed to modify the tumor growth. The total square under the kinetic curves of the tumor growth was by 5.9% less in metformin-treated group (p > 0.05), by 31.8% less in the metformin + melatonin-treated group (p < 0.001) and by 10.2% less in melatonin-treated group (p < 0.01) as compared with the control group.
The anti-tumor effect of combined treatment of metformin + melatonin on the growth of transplantable HER2/neu mammary carcinoma was proved in additional set of the experiment. The dynamics of the tumor growth and survival of tumor-bearing mice from one of these experiments are shown in Figure 4A and B. The treatment inhibited the tumor growth by 40% (p < 0.001) and increased the mean survival time of tumor-bearing mice by 22% (p < 0.05).
The treatment with metformin + melatonin inhibits the growth of solid Ehrlich carcinoma by 40% (p < 0.001) (Fig. 4C ) and increased the mean survival time of the tumor-bearing mice by 22% (p < 0.05) (Fig. 4D) .
respectively. Parameter α of the Gompertz model, which is interpreted as the rate of aging, was not significant changed in any group as compared to the controls.
Spontaneous tumor development in female HER-2/neu transgenic mice. According to the log-rank test age-related distributions of the first mammary adenocarinomas (MAC) occurrence are identical in control and in any treated group (p < 0.05). As shown at Figure 2B , a slower kinetic of tumor incidence was found in metformin-treated mice in comparison with control animals (p < 0.001), with a 50% of tumor-bearing mice revealed at 197 or 223 days of age (+13%) in control and metformin-treated mice, respectively. The treatment with metformin + melatonin or melatonin alone failed to change the kinetics of tumor incidence as well as the mean latent period of tumor appearance ( Table 5) . Thirty six percent of control mice were bearing 9 to 10 tumors per mouse, whereas in the group with metformin 21% of mice were bearing this number of MAC per animal (p > 0.05), in the group treated with metformin + melatonin by 15% (p < 0.01), and in the melatonin alone group-30%. Any treatment failed to influence the mean number of tumors per tumor-bearing mouse, the mean size of MAC, incidence of metastases or their size ( Table 5) .
Effect of metformin and melatonin on the growth of transplantable tumors in mice. The combined treatment with Mean number of tumors per tBM 7 ± 0.5 7 ± 0. hypothalamo-pituitary complex to negative feedback inhibition, reduce excretion of glucocorticoid metabolites and dehydroepiandrosterone-sulfate. 43 It was shown that metformin decreases platelet superoxide anion production in diabetic patients. 47 The capacity of metformin to activate AMPK (AMP-activated protein kinase) has been suggested to constitute an insulin-independent mechanism of inhibitory effect of metformin on proliferation of cancer cells, directly connected with promotion of the inhibition of the AMPK down-stream mammalian effector target of rapamycin (mTOR). 16, [37] [38] [39] 42, 44, 48, 49 mTOR controls cell growth and metabolism in response to nutrients (e.g., amino acids), insulin and growth factors such as IGF-1. 50 Since TOR is activated by nutrients and insulin, calorie restriction deactivates TOR. Calorie restriction extends life span in a variety of species including primates. 51 Recently it was demonstrated that rapamycin like metformin extends life span in mice 52 and delays the development of mammary carcinomas in HER-2/neu transgenic mice (our unpublished observations). Both rapamycin and metformin inhibit carcinogenesis in rodents. 28, [53] [54] [55] [56] Recently it has been observed that metformin induces suppression of HER2 overexpression via direct (AMPK-independent) inhibition of p70S6K1 activity. 8 Discussing the results of our paper showing the geroprotective but not anti-carcinogenic effect of metformin in female SHR mice, 7 Blagosklonny and Campisi 40 suggested the dissociation of metformin effect on aging and on carcinogenesis. The results of the present study are in agreement with this suggestion. In fact, the patterns of metformin effect
Discussion
Our experiments have shown that the treatment with the antidiabetic biguanide metformin increases life span and slows down the development of mammary tumors in female transgenic HER-2/ neu mice. The combined treatment with metformin + melatonin failed to influence the mammary carcinogenesis in transgenic HER2/neu mice whereas it effectively inhibited the growth of transplantable HER2 mammary tumor and Ehrlich carcinoma in mice. These observations are in agreement with the data previously obtained with antidiabetic biguanides (phenformin, buformin and metformin). It was shown in earlier studies that these drugs increased the life span and inhibited spontaneous carcinogenesis in female C3H/Sn mice 14 and in female outbreed rats, inhibited chemical and radiation carcinogenesis in rodents ( Table 6) .
We believe that the results of our new experiment with metformin in long-living mouse strain (which is in progress) will be useful for better understanding the mechanisms of the geroprotective effect of the drug. During the last few years a number of papers on anti-tumor effect of metformin both in vitro and in vivo have been published (Tables 7 and 8 ). There are several suggestions on the mechanism of anti-carcinogenic and anti-tumor effects of metformin. Firstly, metformin is commonly considered to function as a sensitizer to insulin. [43] [44] [45] [46] The anti-diabetics biguanides inhibit fatty acid oxidation, suppress gluconeogenesis in the liver, increase the availability of insulin receptors, inhibit monoamine oxidase, 46 increase sensitivity of Secondly, our results alongside with recent findings of mTOR signaling pathway involvement in regulation of aging 57 and evidence of significant life span extension of mammals with rapamycin and calorie restriction, [50] [51] [52] suggest that mimetic of calorie restriction, anti-diabetic biguanide metformin may be rapidly contemplated for pharmacological intervention at a population level. 10 ad libitum. Cancer prevention study. Experimental design. Seventy five FVB/N HER-2/neu female mice at the age of 2 months were randomly divided into four groups. Mice of the first group were given metformin (Siophor, Berlin-Chemie, Menarini Group) with drinking water (100 mg/kg) 5 times a week to natural death. This dose of metformin is similar to used in our earlier experiments with HER-2/neu mice 5 and equal to 300 mg/m 2 of the surface areas. Recalculation for humans gives in average 510 mg/ml, that is much less than commonly used in clinical practice (1.0-2.5 g per day). Mice of the second group were given melatonin (Sigma Chemical Co., St. Louis, MO) dissolved in tap water (2 mg/l) during the night time (from 18.00 to 09.00 hr) 5 times a week to natural death. Melatonin was used at a dose that has proved effective for life span extension and anti-carcinogenic effect. 5, 10, 60 Melatonin was dissolved in several drops of 96% on the survival and the life span are different in the previous experiment 5 and in present study, whereas the patterns of the drug effect on development of mammary carcinomas very similar and practically identical. However, it is difficult to exclude finally that calorie restriction, metformin and rapamycin may delay cancer by indirect mechanism, slowing age-related processes. The data on the increase of life span and resistance to age-related pathologies in mice with deleted of ribosomal S6 protein kinase 1, a component of mTOR signaling pathway, 57 are in line with this suggestion.
Material and Methods

Animals
It was shown that combination with inhibitors of reactive oxygen species (ROS) formation enhanced the capacity of metformin to suppress HER2 expression. 8 In our experiments the treatment of transplantable HER2 mammary carcinoma and Ehrlich carcinoma with metformin with potent scavenger of ROS melatonin, 12, 58 effectively inhibited the tumor growth. It was shown that melatonin suppressed expression HER2 in mammary adenocarcinomas in transgenic HER2/neu mice. 9, 10, 12 It is worth noting that melatonin represses oxidative stress-induced activation of AMPK and mTOR signaling pathways in hepatoma cells. 59 The available data on mechanisms of anti-tumor and geroprotector effects of melatonin have been discussed elsewhere. 12 In the present experiment the dose of melatonin was 10 time less then that in previous study, 9 that can explain the absence of melatonin effect alone.
Thus, firstly, our results suggest the metformin may be useful in prevention as well as treatment at least of breast cancer. Combined treatment with melatonin may give additional impact on the effects of metformin. We suggest that metformin decreased proliferative activity of cells thus inhibits both the rate of new cancers and the growth of developed tumors. The available data of in vitro as well as of in vivo experiments with transplantable tumors may serve as an additional support this suggestion. water (g) and food (g) per mouse and per body weight unit were calculated. Once every 3 months, daily for 2 weeks, vaginal smears were cytologically examined to determine the estrus function. In the same period, rectal body temperatures of the mice were measured with an electronic thermometer, TPEM (KMIZ, Russia). The time of appearance of mammary tumors was evaluated by palpation, and neoplastic masses were measured with calipers in the two perpendicular diameters. Progressively growing masses of >3 mm in mean diameter were regarded as tumors. Because some treated mice did not display carcinomas in all mammary glands, ethanol and diluted with sterile tap water to a relevant concentration. A fresh melatonin solution which is stable in water solution during 6 months was prepared 3 times a week. Mice of the third group were given melatonin as the mice from group 2 and at other time were given metformin as the mice in the group 1. Mice of the fourth group were given tap water ad libitum. Once a week, all mice were palpated to detect mammary tumors. Localization and size of tumors were registered on special charts. Once a months, all mice were weighed and simultaneously amount of drinking water and food consumed was measured and the rate of consumed tap The size of tumor (volume -V) was determined in formula of ellipsoid:
where A-maximal tumor diameter, B-tumor diameter, perpendicular with A. The tumor inhibition (T) was defined as:
where V C -mean tumor volume in control, V E -mean tumor volume in experimental group. 63 Experiment 3. Fifty six of male SHR mice at the age of 2 months were subcutaneously grafted with 10 5 cells of transplantable Ehrlich carcinoma and then were randomly divided into two groups. Mice of the first group were given metformin with drinking water (100 mg/kg) 5 times a week from 09.00 hrs to 18.00 hrs and melatonin (2 mg/l) from 18.00 to 09.00 hr 5 times a week to natural death. Mice of the second group were given tap water ad libitum. Three times a week all mice were palpated to detect tumors and size of tumors was measured with caliper.
Statistics. Experimental results were statistically processed by the methods of variation statistics with the use of Statgraph statistic program kit. The significance of the discrepancies was defined according to the Student t-criterion, Fisher exact method, χ 2 , non-parametric Mann-Whitney-Wilcoxon test and Friedman RM ANOVA on ranks. 64 Differences in tumor incidence were evaluated by the Mantel-Haenszel logrank test.
Parameters of Gompertz model were estimated using maximum likelihood method, non-linear optimization procedure 65 and self-written code in Matlab; confidence intervals for the parameters were obtained using the bootstrap method. 66 For experimental group Cox regression model 67 was used to estimate relative risk of death and tumor development under the treatment compared to the control group. the mean number of palpable mammary carcinomas/mouse was calculated as the cumulative number of incident tumors/number of tumor-bearing mice.
Pathomorphologic examination. All animals were autopsied. Site, number and size of mammary tumors and metastases to lungs were checked. All tumors, as well as tissues and organs with suspected tumor development were excised and fixed in 10% neutral formalin. After fixation the number of metastases in each lung lobe as well as size of metastases were estimated as recommended by the International Agency for Research on Cancer. 61 After routine histological processing, tissues were embedded in paraffin; 5-7 µm thin histological sections were stained with haematoxylin and eosin and were microscopically examined. Tumors were classified to the IARC recommendations 53 and Annapolis Consensus Report.
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Anti-tumor study. Experimental design. Experiment 1. Forty six FVB/N HER-2/neu male mice at the age of 2 months were subcutaneously grafted with 10 5 cells of transplantable HER2neu mammary carcinoma (the 12 th passage) and then were randomly divided into four groups. Mice of the first group were given metformin with drinking water (100 mg/kg) 5 times a week to natural death. Mice of the second group were given melatonin dissolved in tap water (2 mg/l) during the night time (from 18.00 to 09.00 hr) 5 times a week to natural death. Mice of the third group were given melatonin as the mice from group 2 and at other time were given metformin as the mice in the group 1. Mice of the fourth group were given tap water ad libitum. Three times a week all mice were palpated to detect tumors and size of tumors was measured with caliper.
Experiment 2. Eighteen FVB/N HER-2/neu male mice at the age of 2 months were subcutaneously grafted with 10 5 cells of transplantable HER2neu mammary carcinoma (the 24 th passage) and then were randomly divided into two groups. Mice of the first group were given metformin with drinking water (100 mg/ kg) 5 times a week from 09.00 hrs to 18.00 hrs and melatonin (2 mg/l) from 18.00 to 09.00 hr 5 times a week to natural death. Mice of the second group were given tap water ad libitum. Three times a week all mice were palpated to detect tumors and size of tumors was measured with caliper. The transplanted tumors were measured twice a week.
